Evidence map›Paper›PMID 34497426›Full record

ArticleArchivos de bronconeumologia2022

Lung Function, Radiological Findings and Biomarkers of Fibrogenesis in a Cohort of COVID-19 Patients Six Months After Hospital Discharge.

Belen Safont, Julia Tarraso, Enrique Rodriguez-Borja, Estrella Fernández-Fabrellas, Jose N Sancho-Chust, Virginia Molina, Cecilia Lopez-Ramirez, Amaia Lope-Martinez, Luis Cabanes, Ada Luz Andreu and 9 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Archivos de bronconeumologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04409275 (STUDY OF THE APPEARANCE OF LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION), which is not on this map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04409275 unknown statusnot on this map

STUDY OF THE APPEARANCE OF LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION

TypeobservationalSponsorFundación para la Investigación del Hospital Clínico de ValenciaRan2020 to 2021Enrolled500ConditionsPulmonary Fibrosis
3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Cardiopulmonary Complications after Pulmonary Embolism in COVID-19.International journal of molecular sciences · 2024
    Article
  11. Review
  12. Article
  13. Differential Inflammatory Responses in Adult and Pediatric COVID-19 Patients: Implications for Long-Term Consequences and Anti-Inflammatory Treatment.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 14 institutions in 2 countries.

Belen SafontPulmonary Department, Hospital Clinico, INCLIVA, Valencia, Spain.
Julia TarrasoPulmonary Department, Hospital Clinico, INCLIVA, Valencia, Spain.
Enrique Rodriguez-BorjaLaboratory of Biochemistry and Molecular Pathology, Hospital Clinico de Valencia, Valencia, Spain.
Estrella Fernández-FabrellasPulmonary Department, Hospital General, Valencia, Spain.
Jose N Sancho-ChustPulmonary Department, Hospital San Juan, Alicante, Spain.
Virginia MolinaPulmonary Department, Hospital Vinalopo de Elche, Alicante, Spain.
Cecilia Lopez-RamirezPulmonary Department, Hospital Virgen del Rocio, Sevilla, Spain.
Amaia Lope-MartinezLaboratory of Biochemistry and Molecular Pathology, Hospital Clinico de Valencia, Valencia, Spain.
Luis CabanesPulmonary Department, Hospital La Ribera, Alzira, Valencia, Spain.
Ada Luz AndreuPulmonary Department, Hospital los Arcos, Murcia, Spain.
Susana HerreraPulmonary Department, Hospital Dr Peset, Valencia, Spain.
Carolina LahosaPulmonary Department, Hospital Arnau de Vilanova, Valencia, Spain.
Jose Antonio RosPulmonary Department, Hospital Virgen de la Arraixaca, Murcia, Spain.
Juan Luis Rodriguez-HermosaPulmonary Department, Hospital Clinico San Carlos, Medical Department, School of Medicine, Universidad Complutense, Madrid, Spain.
Joan B SorianoCOVID-19 Clinical Management Team, World Health Organization, Geneva, Switzerland; Hospital La Princesa, Madrid, Spain.
Ines Moret-TatayInflammatory Bowel Disease Research Group/Multiplex Analysis Unit, IIS Hospital la Fe, Valencia, Spain.
Juan Antonio Carbonell-AsinsBioinformatics and Biostatistics Unit, INCLIVA, Valencia, Spain.
Alba MuletPulmonary Department, Hospital Clinico, INCLIVA, Valencia, Spain.
Jaime Signes-CostaPulmonary Department, Hospital Clinico, INCLIVA, Valencia, Spain. Electronic address: jaimesignescosta@gmail.com.
INCLIVA Health Research Institute · ESHospital Clínico Universitario de Valencia · ESHospital Arnau de Vilanova · ESHospital Clínico San Carlos · ESHospital de La Ribera · ESHospital General Universitario De Valencia · ESHospital General Universitario Los Arcos del Mar Menor · ESHospital Universitario del Vinalopó · ESHospital Universitario Doctor Peset · ESHospital Universitario Virgen de la Arrixaca · ESHospital Universitario Virgen del Rocío · ESHospital Universitari Sant Joan D'Alacant · ESInstituto de Investigación Sanitaria La Fe · ESWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

introductionImpairment in pulmonary function tests and radiological abnormalities are a major concern in COVID-19 survivors. Our aim is to evaluate functional respiratory parameters, changes in chest CT, and correlation with peripheral blood biomarkers involved in lung fibrosis at two and six months after SARS-CoV-2 pneumonia.

methodsCOVID-FIBROTIC (clinicaltrials.gov NCT04409275) is a multicenter prospective observational cohort study aimed to evaluate discharged patients. Pulmonary function tests, circulating serum biomarkers, chest radiography and chest CT were performed at outpatient visits.

resultsIn total, 313, aged 61.12 ± 12.26 years, out of 481 included patients were available. The proportion of patients with DLCO < 80% was 54.6% and 47% at 60 and 180 days. Associated factors with diffusion impairment at 6 months were female sex (OR: 2.97, 95%CI 1.74-5.06,

conclusionAlmost half of patients with moderate or severe COVID-19 pneumonia had impaired pulmonary diffusion six months after discharge. Severe patients showed fibrotic lesions in CT scan and elevated serum biomarkers involved in pulmonary fibrosis.

Indexed as

6-MWT, 6 minute-walk testARDS, acute respiratory distress syndromeBMI, body mass indexChest CTCOPD, chronic obstructive pulmonary diseaseCOVID-19, coronavirus disease 2019COVID-19 sequelaeCT, computed tomographyDLCO, diffusing capacity for carbon monoxideFibrotic changesGGO, ground-glass opacityHFNC, high flow nasal cannula oxygenILD, interstitial lung diseaseIMV, mechanical ventilationInterstitial lung diseaseLung diffusionMMP, matrix metalloproteinasesmMRC, modified British Medical Research CouncilNIV, non-invasive ventilationRALE, radiographic assessment of lung edemaRT-PCR, reverse transcriptase-polymerase chain reactionSARS-CoV-2, severe acute respiratory syndrome coronavirus 2SARS, severe acute respiratory syndromesEGFR, soluble epidermal growth factor receptorSerum biomarkersVEGF, vascular endothelial growth factor

Identifiers

PMID34497426
PMCPMC8414844
OpenAlexW3197287238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.